| Treatment Group |
Ad5 nAb* |
N** |
Injection schedule months (days) |
| 0 (0) |
1 (28) |
2 (56) |
6 (168) |
| 1 |
<18 |
34/6 |
rAd5 |
- |
- |
rAd5 |
| 2 |
<18 |
48/8 |
DNA |
DNA |
DNA |
rAd5 |
| 3 |
<18 |
48/8 |
DNA |
DNA |
DNA |
rAd35 |
| 4 |
≥18 |
34/6 |
DNA |
DNA |
DNA |
rAd35 |
| Total |
|
192 164/28 |
|
|
|
|
|
| *Adenovirus 5 (Ad5) neutralizing antibody (nAb) ≥ 18 represents Ad5 seropositive individuals; **N represents the active vaccinees/placebo recipients who were blinded to treatment assignment within each treatment group. DNA vaccinations were delivered by Biojector, and adenovectors were delivered by needle and syringe. Groups 2 and 3 were blinded to assignment to these groups. |
| Table 1: HVTN 077 Protocol Schema. |
